Metasol

Methylprednisolone Hydrogen Succinate, the active ingredient in Metasol, is a corticosteroid presented as an injectable solution for intramuscular and intravenous use. It treats inflammatory, autoimmune and severe allergic conditions in adults and children as prescribed by a physician.

GNH USA supplies Metasol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metasol, a glucocorticoid, is employed in a range of inflammatory and immune‑mediated disorders. - Inflammatory and autoimmune disorders: reduces inflammation and modulates immune response. - Severe allergic reactions: rapidly suppresses hypersensitivity and edema. - Asthma exacerbations: improves airway function by decreasing airway inflammation. - Rheumatic diseases: alleviates joint swelling and pain. - Adrenal insufficiency: provides glucocorticoid replacement when endogenous production is inadequate.

Adverse reactions may vary with dose, duration and individual susceptibility.

Common Side Effects: - Hyperglycaemia: elevated blood glucose levels. - Fluid retention: swelling, weight gain, or hypertension. - Insomnia: difficulty sleeping. - Mood changes: irritability, anxiety or euphoria. - Gastrointestinal irritation: dyspepsia or ulcer risk. - Increased infection risk: reduced immune defence.

Serious or Rare Side Effects: - Adrenal suppression: potential for adrenal crisis on abrupt withdrawal. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypertension: sudden rise in blood pressure. - Psychosis or severe mood disorders. - Osteonecrosis: bone tissue death, especially in joints. - Opportunistic infections: fungal or viral infections in immunocompromised patients.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for complications. - Infection risk assessment: screen for active infections before use. - Blood glucose monitoring: especially in diabetic patients. - Bone health evaluation: consider calcium/vitamin D supplementation for long‑term therapy. - Tapering plan: gradually reduce dose after prolonged treatment to avoid adrenal insufficiency. - Avoid in systemic fungal infection unless benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and direct light.

Methylprednisolone may alter the pharmacokinetics or pharmacodynamics of several medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase steroid exposure. - Live vaccines: risk of vaccine‑derived infection. - NSAIDs: heightened gastrointestinal bleeding risk. - Anticoagulants (warfarin): enhanced anticoagulant effect. - Loop diuretics: may exacerbate potassium loss.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce steroid efficacy. - Antidiabetic agents: possible hypoglycaemia or hyperglycaemia. - ACE inhibitors: potential for fluid retention and hypertension. - Antihistamines: may mask early signs of hypersensitivity. - Non‑live vaccines: monitor immune response effectiveness.